Key Takeaways
- AHK-Cu (L-alanyl-L-histidyl-L-lysine-Cu²⁺) has been studied in exactly one published experiment on human tissue — a 2007 laboratory study on isolated hair follicles and cultured dermal papilla cells[1]
- No human clinical trial of AHK-Cu has ever been conducted, and no pharmacokinetic study exists, so there is no measured bioavailability, half-life or blood level for this peptide by any route
- No published study has injected AHK-Cu into a human being. Injection protocols circulating online are vendor convention, not research findings
- The 2007 study found effects at picomolar to nanomolar concentrations (10⁻¹² to 10⁻⁹ M) — millions of times lower than the percentages sold in topical products
- AHK-Cu is a cosmetic ingredient, not an FDA-approved drug, and it is not on the WADA prohibited list
- Its better-studied relative GHK-Cu carries substantially more published evidence, and much of what circulates as "AHK-Cu research" is actually GHK-Cu research
What AHK-Cu Actually Is
AHK-Cu is a three–amino-acid peptide — alanine, histidine, lysine — bound to a copper(II) ion. In cosmetic ingredient listings it is generally sold under the name Copper Tripeptide-3.
It is frequently confused with GHK-Cu, and the confusion is not harmless. The two differ by a single amino acid: GHK begins with glycine, AHK with alanine. That one substitution changes the mass, and it changes which body of research applies.
| AHK-Cu | GHK-Cu | |
|---|---|---|
| Sequence | Ala-His-Lys + Cu²⁺ | Gly-His-Lys + Cu²⁺ |
| Free peptide mass | 354.40 Da | 340.38 Da |
| Copper complex mass | 415.93 Da | 401.91 Da |
| Occurs naturally in humans | No — synthetic | Yes — found in plasma |
| Published studies naming it | 1 | Dozens |
If you have read that AHK-Cu weighs 340 Da, that figure is GHK's, not AHK's. It is one of the more common errors in circulation, and it is a reliable signal that whatever else the source says about AHK-Cu was probably written about GHK-Cu.
Can You Inject AHK-Cu?
This is the most common question asked about this peptide, so it deserves a direct answer rather than a protocol table.
No published study has ever injected AHK-Cu into a human. A search of PubMed for AHK-Cu combined with injection, subcutaneous or intradermal administration returns nothing. The single AHK-Cu study applied the peptide to isolated tissue in a dish[1]. There is no injected dose, no injection interval, and no injection safety data for this molecule, because the experiment has not been done.
That means any "AHK-Cu injection protocol" — including doses in milligrams, weekly schedules, or reconstitution volumes — is a vendor or forum convention. It may describe what people do. It does not describe what has been tested.
The closest thing to real evidence
One human study comes near this question, and it is worth understanding precisely because of what it does and does not show.
In 2018, Kapoor and Shome reported intradermal scalp injections in 1,000 patients using a formulation that contained copper tripeptide-1 alongside vascular endothelial growth factor, basic fibroblast growth factor, insulin-like growth factor, keratinocyte growth factor and thymosin β4. Patients received injections every three weeks for eight sessions. Eighty-three percent showed reduced hair fall on the hair pull test, and total hair count remained significantly increased at one year (p = 0.002). Treatment was well tolerated[2].
Four caveats determine how much weight that carries:
- The copper peptide used was copper tripeptide-1 — GHK-Cu, not AHK-Cu.
- It was one of six active ingredients, so no effect can be attributed to the copper peptide specifically.
- The study was open-label and single-arm with no control group, which is the design most prone to overstating benefit in hair-loss research.
- The route was intradermal into the scalp, performed in a clinic — not subcutaneous self-injection.
A 2026 narrative review in the American Journal of Sports Medicine assessed injectable peptide therapy across the compounds most marketed to patients and concluded that while GHK-Cu shows promise in wound healing and anti-inflammatory work, no clinical data support its injectable use[3]. That conclusion applies with more force to AHK-Cu, which has a fraction of GHK-Cu's evidence.
Why copper changes the risk calculation
Copper peptides are not simply peptides. Copper is a trace metal the body regulates tightly, and the topical route the research used keeps exposure local. Injection bypasses that. There is no published measurement of what systemic copper load results from injecting a copper peptide, at any dose, which means the question cannot currently be answered from evidence in either direction.
Injection would also work against the target
There is a further problem, and it is a matter of reasoning about delivery rather than a study finding.
Injection is usually assumed to be the more potent route, on the logic that it bypasses absorption barriers. For a molecule whose target is a specific patch of scalp, that logic runs backwards. A subcutaneous injection distributes a compound through the systemic circulation, diluting it across the whole body before any of it reaches the dermal papilla cells at a thinning hairline. Topical application to the scalp is the more targeted route, not the weaker one.
This is also why the one human study that comes closest used intradermal injection directly into scalp skin rather than subcutaneous injection[2] — the delivery was deliberately local.
Research-grade material is not made for injection
Separately from what the molecule does, there is the question of what is in the vial.
Sterility, endotoxin limits and particulate control are properties of a manufacturing process, not of a peptide. Material sold as "research grade" or "not for human consumption" is not produced to the standards required for anything entering the body, and purity testing by HPLC measures how much of the compound is present — not whether the preparation is sterile or endotoxin-free. Those are different tests, and a certificate of analysis showing 99% purity does not speak to either.
What the Only AHK-Cu Study Found
The single published AHK-Cu experiment came from the Department of Dermatology at Seoul National University and appeared in Archives of Pharmacal Research in 2007[1]. It is worth reporting in detail, because it is the entire evidence base.
Researchers applied AHK-Cu to two preparations: human hair follicles isolated and kept alive outside the body, and cultured dermal papilla cells — the specialised fibroblasts at the base of a follicle that govern whether hair grows.
What it showed. At concentrations from 10⁻¹² to 10⁻⁹ M, AHK-Cu stimulated elongation of the isolated follicles and proliferation of dermal papilla cells. At 10⁻⁹ M, the ratio of Bcl-2 to Bax rose and the cleaved forms of caspase-3 and PARP fell — a pattern consistent with cells being protected from programmed cell death.
What it did not show. The reduction in the number of apoptotic dermal papilla cells at 10⁻⁹ M did not reach statistical significance, a limitation the authors state plainly. The work also confirmed a general property of tripeptide-copper complexes: they increase dermal fibroblast proliferation and vascular endothelial growth factor production while decreasing transforming growth factor-beta1 secretion.
This is a genuine and reasonably encouraging result. It is also a laboratory result on isolated tissue, and nineteen years later it has not been followed by a human trial.
The Concentration Gap Nobody Mentions
The 2007 study found its effects between 10⁻¹² and 10⁻⁹ M. Converting those to the units products are sold in is revealing:
| Concentration | Molar equivalent | Relative to the top of the studied range |
|---|---|---|
| Studied range | 10⁻¹² – 10⁻⁹ M | baseline |
| 0.01% topical | 2.4 × 10⁻⁴ M | ~240,000× higher |
| 0.1% topical | 2.4 × 10⁻³ M | ~2.4 million× higher |
| 1% topical | 2.4 × 10⁻² M | ~24 million× higher |
| 7–10% concentrate | 0.17 – 0.24 M | ~168–240 million× higher |
There is a legitimate reason a topical product is not formulated at 10⁻⁹ M: a molecule applied to intact skin must cross the stratum corneum, and only a fraction of what is applied reaches living tissue. Formulators compensate by increasing concentration.
But the size of that gap has never been measured for AHK-Cu. No skin-penetration study of this peptide exists, so nobody can say what tissue concentration a 1% solution actually produces, or whether it lands anywhere near the range that worked in the dish. Treat any product claiming a specific percentage is "optimal" with scepticism — the study that would establish optimal has not been run.
Worth noting too: the 2007 data showed effects at the low end of its range. More is not established to be better, and copper peptides have shown reduced activity at higher concentrations in other contexts.
Topical Concentrations Used in Practice
The figures below describe what the market sells, not what research validates. They are formulation convention, offered so you can interpret a label — not a recommendation.
| Product type | Typical concentration | Notes |
|---|---|---|
| Finished cosmetic sprays and serums | 0.05% – 1% | The form with the longest commercial history |
| Combined AHK-Cu / GHK-Cu formulas | 1:1 ratio, varying totals | Marketed for scalp use |
| Raw liposomal concentrates | 7% – 10% | Sold for dilution, not direct use |
| Lyophilised powder | Sold by mass | Requires reconstitution |
Copper peptide solutions are naturally blue to blue-violet. That colour comes from the copper complex itself. A solution that has turned brown, green or colourless has degraded, and the copper-peptide complex is also destabilised below about pH 5.0 — which is why layering these with low-pH vitamin C or exfoliating acid products is generally discouraged.
How AHK-Cu Is Thought to Work
The mechanism below is drawn from the 2007 study and from the broader copper-tripeptide literature. It describes plausible biology, not demonstrated clinical benefit.
Dermal papilla cells. These specialised fibroblasts sit at the base of each follicle and control the hair cycle. AHK-Cu increased their proliferation in culture[1].
Anti-apoptotic signalling. The rise in Bcl-2/Bax ratio and fall in cleaved caspase-3 and PARP point toward cells being held back from programmed death — the process that drives follicle miniaturisation[1].
VEGF and TGF-β1. Tripeptide-copper complexes raise vascular endothelial growth factor, which supports the blood supply feeding a follicle, and lower transforming growth factor-beta1, a signal associated with the follicle entering its regression phase[1].
The honest summary is that this is a coherent mechanistic story with laboratory support and no clinical confirmation.
Storage and Handling
These are properties of peptide chemistry, and they hold regardless of the evidence question.
- Lyophilised powder is stable frozen. Keep it dry and dark; moisture is the main enemy.
- Reconstituted or in-solution product belongs refrigerated, and copper peptide solutions degrade faster at room temperature and in light.
- Colour is your indicator. Blue to blue-violet is intact. Brown, green or colourless means degraded.
- Avoid low pH. Below roughly pH 5.0 the copper-peptide complex destabilises.
- Do not combine in the same application with strong acids or high-concentration vitamin C.
Safety and Who Should Be Careful
No formal safety study of AHK-Cu exists in humans, so the following reflects the general behaviour of topical copper peptides rather than trial data.
Reported effects with topical copper peptides are typically local: irritation, itching, redness at the application site, and occasional contact sensitivity in people who react to copper or to peptide preservatives. Applying to broken or infected skin, or near the eyes, is generally avoided.
Greater caution is warranted for anyone with Wilson's disease or another copper-handling disorder, since these conditions impair the body's ability to regulate copper. People who are pregnant or breastfeeding have not been studied. Neither have children.
Because there is no systemic exposure data for AHK-Cu by any route, the safety of injected or large-surface-area use cannot be characterised.
